Silo Pharma (NASDAQ:SILO) Stock Price Down 4.1% – Time to Sell?

Silo Pharma, Inc. (NASDAQ:SILO) dropped 4.1% during trading on Monday . The stock traded as low as $2.92 and last traded at $3.07. Approximately 50,587 shares changed hands during mid-day trading, a decline of 7% from the average session volume of 54,515 shares. The stock had previously closed at $3.20.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Silo Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Silo Pharma Price Performance

The stock has a market capitalization of $3.85 million, a P/E ratio of -0.70 and a beta of 0.71. The stock’s fifty day moving average is $5.16 and its 200-day moving average is $5.52.

Silo Pharma (NASDAQ:SILO) last posted its earnings results on Thursday, August 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.44). Silo Pharma had a negative return on equity of 81.75% and a negative net margin of 6,726.39%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. DRW Securities LLC bought a new stake in Silo Pharma during the fourth quarter worth approximately $113,000. AdvisorShares Investments LLC raised its position in shares of Silo Pharma by 64.3% in the fourth quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock valued at $204,000 after purchasing an additional 234,629 shares during the period. Virtu Financial LLC bought a new position in shares of Silo Pharma in the third quarter valued at approximately $74,000. Finally, Geode Capital Management LLC lifted its stake in shares of Silo Pharma by 134.6% in the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock worth $32,000 after buying an additional 53,309 shares during the last quarter. 5.58% of the stock is owned by institutional investors.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.